Liquid biopsy biomarkers for bladder cancer diagnostics: LiqBio-BC

Bladder cancer (BC) is a common public health problem worldwide and a major cause of morbidity and mortality, resulting in significant treatment costs over the patient's lifetime. Due to the high tumours heterogeneity, there is poor risk stratification, emergence of treatment resistance, and ultimately poor clinical outcome.
The project aims to develop an innovative diagnostic test for early non-invasive bladder cancer diagnostics using epigenetic markers, isolated from urine exosomes. The test will increase healthy life years, reduce treatment costs, and enhance collective knowledge via AI.
Project's mission is to shift bladder cancer detection from hospitals to primary care, empowering earlier diagnosis, better treatment choice, higher survival rates and lower costs.